Pfizer Is Still One of the Healthcare Sector’s Best Dividend Yielders


PFE stock is trading at a reasonable valuation, and is still worth owning despite dividend-cut rumors


For many years, income-oriented investors have counted on healthcare giant Pfizer (NYSE:PFE) stock to provide reliable dividend distributions.


In fact, it’s not unreasonable to say that this is among the main benefits of holding PFE stock for the long term.


However, nothing in the markets is 100% reliable and some folks have been talking about a Pfizer dividend cut.


Is there a dividend payout reduction coming? In light of an important merger in the health-care sector, Pfizer’s stakeholders should know what to expect.


As we’ll see, there’s no need to lose faith in the company or the stock. Income and value investors alike should continue to rely on Pfizer as a premier business that consistently rewards its loyal shareholders.



A Closer Look at PFE Stock

Speaking of value investing, PFE stock’s trailing 12-month price-to-earnings ratio is currently 19.83.


That’s quite reasonable as it suggests that the stock’s price is justified by the company’s profits.


Continue reading …



No comments:

Post a Comment